Moneycontrol
HomeNewsBusinessMoneycontrol ResearchSun Pharma’s steady India business and US speciality portfolio should help it do well in FY22
Trending Topics
Sensex Live
Pine Labs IPO Day 1
Groww IPO Day 3 GMP
Upcoming IPOs
Gold Rate

Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

Anubhav Sahu   •

What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More